Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given an average recommendation of “Hold” by the nine ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $31.8333.

A number of analysts recently issued reports on the company. Wedbush reaffirmed a “neutral” rating and issued a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target on the stock in a research report on Tuesday, January 20th. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th.

Institutional Trading of Sutro Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of STRO. Velan Capital Investment Management LP grew its stake in shares of Sutro Biopharma by 2.0% in the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock valued at $2,709,000 after acquiring an additional 60,000 shares in the last quarter. UBS Group AG raised its position in shares of Sutro Biopharma by 14.0% in the third quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after buying an additional 226,955 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after buying an additional 1,206,330 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Sutro Biopharma in the second quarter valued at approximately $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma in the third quarter valued at approximately $387,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO stock opened at $22.93 on Wednesday. The stock has a market capitalization of $195.23 million, a P/E ratio of -0.88 and a beta of 1.47. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $26.54. The business has a 50-day moving average of $17.37 and a 200-day moving average of $12.26.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.